Polymeric particles for sustained delivery of multimodal peptide therapeutics
JHU Ref #: C11250
Value Proposition
· Stability: polymeric nanoparticle encapsulation increases and sustains peptide residence time, for increased accumulation in tissue vasculature and maximize treatment effects
· Safety: use of nanoparticles reduces toxicity by confining peptide delivery to site of administration
· Flexible formulation approaches: system's versatility allows for multiple formulation approaches – from injectable powders to topical creams and implantable devices – making it adaptable to various clinical needs
· Broad therapeutic applications: tunable delivery system platform can be applied to various peptide/polymer combinations, offering flexibility for multiple therapeutic applications (cancer, AMD, cardiovascular, etc.)
Unmet Need
· Traditional peptide therapeutics often suffer from poor stability and short shelf-life, limiting their clinical utility. Such peptides typically face barriers in reaching their target sites effectively due to degradation and poor bioavailability. There is a need for a delivery system capable of effective, sage, and controlled release of peptides and other biomolecule cargo. In addition, such a drug delivery system should be adaptable to multiple diseases and administration routes.
Technology Description
· Researchers at Johns Hopkins have developed an innovative drug delivery system that addresses fundamental limitations in peptide therapeutics through advanced polymer engineering (. The platform utilizes proprietary polymeric nanoparticles to encapsulate peptide drugs, creating stable formulations that protect the therapeutic payload from degradation while enabling controlled release at target sites. By combining the specificity of peptide therapeutics with the protective and targeting capabilities of polymer nanoparticles, this platform overcomes traditional barriers including enzymatic degradation, poor membrane permeability, and rapid clearance that have historically limited peptide drug development. Key applications span oncology, ophthalmology (particularly for age-related macular degeneration treatment), and cardiovascular medicine, positioning this as a true platform technology rather than a single-product solution.
Stage of Development
· In vitro and in vivo pre-clinical proof-of-concept experiments have been completed; technology protected via issued patents (US9717694B2 and US10786463B2)
Data Availability: Data available upon request.
Publication: N/A
License Availability: Limited to the issued patents listed here only.
